File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Improved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution

TitleImproved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution
Authors
Issue Date2020
Citation
Bone Marrow Transplantation, 2020, v. 55, n. 5, p. 929-938 How to Cite?
AbstractT-cell depletion of an HLA-haploidentical (haplo) graft is often used to reduce the risk of graft-versus-host disease (GVHD), but the lack of donor T cells in the infused product may lead to graft failure, slow T-cell reconstitution, infections, and relapse. More selective T-cell depletion targeting CD45RA can effectively deplete naive T cells but preserve large numbers of memory T cells leading to robust engraftment of diverse T-cell populations and reduction of viremia in the early posttransplant period. Herein, we report the outcome of 143 pediatric and young adult hematologic malignancy patients receiving a first allogeneic hematopoietic cell transplantation (HCT) on six consecutive ex vivo T-cell depleted haploHCT protocols over the past 15 years at a single institution—including the first 50 patients on an active CD45RA-depleted haploHCT study in which patients also received NK-cells and pharmacological GvHD prophylaxis post transplant. Our data demonstrated an increase in the 3-year overall survival and event-free survival in nonchemorefractory recipients receiving CD45RA-depleted grafts (78.9% and 77.7%, respectively) compared with historic T-cell depleted haploHCT cohorts (46.7% and 42.7%, respectively, p = 0.004, and 0.003). This improvement was primarily due to a reduction in transplant related mortality without significant increase in the rates of GVHD.
Persistent Identifierhttp://hdl.handle.net/10722/294484
ISSN
2020 Impact Factor: 5.483
2015 SCImago Journal Rankings: 1.585
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMamcarz, Ewelina-
dc.contributor.authorMadden, Renee-
dc.contributor.authorQudeimat, Amr-
dc.contributor.authorSrinivasan, Ashok-
dc.contributor.authorTalleur, Aimee-
dc.contributor.authorSharma, Akshay-
dc.contributor.authorSuliman, Ali-
dc.contributor.authorMaron, Gabriela-
dc.contributor.authorSunkara, Anusha-
dc.contributor.authorKang, Guolian-
dc.contributor.authorLeung, Wing-
dc.contributor.authorGottschalk, Stephen-
dc.contributor.authorTriplett, Brandon M.-
dc.date.accessioned2020-12-03T08:22:50Z-
dc.date.available2020-12-03T08:22:50Z-
dc.date.issued2020-
dc.identifier.citationBone Marrow Transplantation, 2020, v. 55, n. 5, p. 929-938-
dc.identifier.issn0268-3369-
dc.identifier.urihttp://hdl.handle.net/10722/294484-
dc.description.abstractT-cell depletion of an HLA-haploidentical (haplo) graft is often used to reduce the risk of graft-versus-host disease (GVHD), but the lack of donor T cells in the infused product may lead to graft failure, slow T-cell reconstitution, infections, and relapse. More selective T-cell depletion targeting CD45RA can effectively deplete naive T cells but preserve large numbers of memory T cells leading to robust engraftment of diverse T-cell populations and reduction of viremia in the early posttransplant period. Herein, we report the outcome of 143 pediatric and young adult hematologic malignancy patients receiving a first allogeneic hematopoietic cell transplantation (HCT) on six consecutive ex vivo T-cell depleted haploHCT protocols over the past 15 years at a single institution—including the first 50 patients on an active CD45RA-depleted haploHCT study in which patients also received NK-cells and pharmacological GvHD prophylaxis post transplant. Our data demonstrated an increase in the 3-year overall survival and event-free survival in nonchemorefractory recipients receiving CD45RA-depleted grafts (78.9% and 77.7%, respectively) compared with historic T-cell depleted haploHCT cohorts (46.7% and 42.7%, respectively, p = 0.004, and 0.003). This improvement was primarily due to a reduction in transplant related mortality without significant increase in the rates of GVHD.-
dc.languageeng-
dc.relation.ispartofBone Marrow Transplantation-
dc.titleImproved survival rate in T-cell depleted haploidentical hematopoietic cell transplantation over the last 15 years at a single institution-
dc.typeArticle-
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1038/s41409-019-0750-7-
dc.identifier.pmid31740766-
dc.identifier.pmcidPMC7202974-
dc.identifier.scopuseid_2-s2.0-85075357404-
dc.identifier.volume55-
dc.identifier.issue5-
dc.identifier.spage929-
dc.identifier.epage938-
dc.identifier.eissn1476-5365-
dc.identifier.isiWOS:000563845700013-
dc.identifier.issnl0268-3369-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats